2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135762
    Allylescaline hydrochloride 39201-76-8 98%
    Allylescaline hydrochloride is a derivative of the phenethylamine Escaline in which an allyl group replaces the ethyl group.
    Allylescaline hydrochloride
  • HY-135907
    (Rac)-AZ8838 2100283-63-2 98%
    (Rac)-AZ8838 (P69, Example 1) is a conformational antagonist of proteinase-activated receptor 2 (PAR2), which can be used for the study of pain and inflammation-related diseases.
    (Rac)-AZ8838
  • HY-13596R
    Cisatracurium besylate (Standard) 96946-42-8
    Cisatracurium (besylate) (Standard) is the analytical standard of Cisatracurium (besylate). This product is intended for research and analytical applications. Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.
    Cisatracurium besylate (Standard)
  • HY-13649R
    Indibulin (Standard) 204205-90-3 98%
    Indibulin (Standard) is the analytical standard of Indibulin. This product is intended for research and analytical applications. Indibulin (ZIO 301), an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis.
    Indibulin (Standard)
  • HY-136679
    TD114-2 436866-52-3 98%
    TD114-2 (cmpound 29) is a potent and highly selective inhibitor of glycogen synthase kinase-3β (GSK-3β) (IC50=48 nM). TD114-2 is associated with the hydrogen bond formation of arginine 141 (ARG141) specific to GSK-3β, an amino acid that is often a negatively charged residue in other kinases, which determines the high selectivity of GSK-3β. TD114-2 can be used in the study of diabetes, neurodegenerative diseases and other diseases associated with GSK-3β.
    TD114-2
  • HY-136700
    SB-699551 free base 791789-61-2 98%
    SB-699551 free base is a selective and brain penetrant 5-HT5A receptor antagonist with a pKi of 8.2 nM. SB-699551 free base shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 free base disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 free base can be used for the research of anxiety, breast cancer, and Alzheimer's disease.
    SB-699551 free base
  • HY-136942
    DS1 372497-52-4 98%
    DS1 is a potent GABAA agonist. DS1 increases the activity of serum response element (SRE) and cAMP response element (CRE) promoters. DS1 induces luteinizing hormone beta (LHbeta) and follicle-stimulating hormone beta (FSHbeta) promoter activity.
    DS1
  • HY-136947
    RJR-2429 91556-75-1 98%
    RJR-2429 is a nAChR agonist (EC50: 59 nM). RJR-2429 binds with high affinity to α4β2 receptor subtype (Ki = 1 nM). RJR-2429 induces ileum contraction.
    RJR-2429
  • HY-136967
    Mergocriptine 81968-16-3 98%
    Mergocriptine (CBM36-733) is a dopamine receptor agonist and SARS-CoV-2 Mpro ligand. Mergocriptine regulates ambulatory activity.
    Mergocriptine
  • HY-137016
    8-Pcpt-cGMP 54364-02-2 98%
    8-Pcpt-cGMP is an agonist for cyclic nucleotide-gated (CNG) channel with an EC50 of 0.5 μM. 8-Pcpt-cGMP exhibits good membrane permeability. 8-Pcpt-cGMP can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction.
    8-Pcpt-cGMP
  • HY-137045
    Bisindolylmaleimide VII 137592-47-3 98%
    Bisindolylmaleimide VII is a potent inhibitor of calmodulin with high affinity for calmodulin (Kd=186.2 nM). Bisindolylmaleimide VII is used to study the role of calmodulin in cancer, neurodegenerative diseases, and muscle dysfunction.
    Bisindolylmaleimide VII
  • HY-137064
    Memantine lactose adduct 1159637-28-1 98%
    Memantine lactose adduct is a lactose adduct of Memantine (HY-B0591) and an intermediate in the synthesis of adamantane amine antibiotics.
    Memantine lactose adduct
  • HY-137108
    Sp-8-pCPT-cGMPS 160385-87-5 98%
    Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of protein kinase G (types I α, I β, and II) and protein kinase A type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission.
    Sp-8-pCPT-cGMPS
  • HY-137161
    6-Nitroquipazine 77372-73-7 98%
    6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a Ki of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression.
    6-Nitroquipazine
  • HY-137162
    Dotarizine 84625-59-2 98%
    Dotarizine is a novel Piperazine (HY-B0912) derivative and antimigraine agent. Dotarizine exhibits Ca2+ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect.
    Dotarizine
  • HY-137254
    SKF-80723 71636-62-9 98%
    SKF-80723 is a D1 receptor agonist and can be used for study of Parkinson's disease.
    SKF-80723
  • HY-13735R
    Quinacrine (Standard) 83-89-6 98%
    Quinacrine (Standard) is the analytical standard of Quinacrine. This product is intended for research and analytical applications. Quinacrine (Acriquine) is an antimalarial and anti-cancer agent. Quinacrine also inhibits human aldehyde oxidase (IC50: 3.3 μM). Quinacrine has affinity for nucleic acids, and stains DNA and RNA in fixed cells (Ex/Em: 436/525 nm).
    Quinacrine (Standard)
  • HY-137543
    Δ8-Tetrahydrocannabivarin 31262-38-1 98%
    Δ8-Tetrahydrocannabivarin is a cannabinoid.
    Δ8-Tetrahydrocannabivarin
  • HY-137633
    Sp-8-Br-PET-cGMPS 172806-21-2 98%
    Sp-8-Br-PET-cGMPS is a membrane-permeable PKG agonist and a membrane-permeable inhibitor of retinal-type cGMP-gated ion channels, as well as an activator of cGMP-dependent protein kinases I α and I β. Sp-8-Br-PET-cGMPS is resistant to mammalian cyclic nucleotide-dependent phosphodiesterases, has no metabolic side effects, and is more lipophilic and permeable than Sp-8-pCPT-cGMPS. Sp-8-Br-PET-cGMPS can be used to study the role of cGMP signaling pathways in the nervous system.
    Sp-8-Br-PET-cGMPS
  • HY-137635
    Sp-6-Phe-cAMPS 169335-92-6 98%
    Sp-6-Phe-cAMPS is a potent, site-selective and membrane-permeable activator of cAMP-dependent protein kinase. Sp-6-Phe-cAMPS does not activate exchange factors directly activated by cAMP and can therefore be used as an Epac negative control. Sp-6-Phe-cAMPS can be used in the study of neurodegenerative diseases.
    Sp-6-Phe-cAMPS
Cat. No. Product Name / Synonyms Application Reactivity